Literature DB >> 1643701

Renal handling of carboplatin.

B T Sørensen1, A Strömgren, P Jakobsen, J T Nielsen, L S Andersen, A Jakobsen.   

Abstract

The mechanism for renal handling of carboplatin was studied in 17 ovarian cancer patients treated with a combination of carboplatin and cyclophosphamide. Carboplatin and [51Cr]-ethylenediaminetetraacetic acid (EDTA) renal clearances were measured simultaneously during short intervals of from 45 to 120 min. A total of 131 clearance intervals were analyzed during 35 chemotherapy courses. The carboplatin/[51Cr]-EDTA clearance ratio (R) served as an indicator of the net tubular reabsorption (R less than 1) or secretion (R greater than 1). The R value was calculated for each sampling interval. No significant difference was found between interpatient and intertreatment variation. The intertreatment variation as tested against the variation in the short intervals by an F-test was highly significant. We calculated the average R value for each treatment and consequently based our results on a total of 35 observations. The mean R value was 0.77 (t-test for R = 1; P less than 0.001). We conclude that the renal elimination of carboplatin takes place by glomerular filtration followed by tubular reabsorption.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1643701     DOI: 10.1007/bf00686302

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans?

Authors:  L S Freedman; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  A simple method for the determination of glomerular filtration rate.

Authors:  J Bröchner-Mortensen
Journal:  Scand J Clin Lab Invest       Date:  1972-11       Impact factor: 1.713

3.  Pharmacokinetics of carboplatin after i.v. administration.

Authors:  F Elferink; W J van der Vijgh; I Klein; J B Vermorken; H E Gall; H M Pinedo
Journal:  Cancer Treat Rep       Date:  1987-12

4.  Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma.

Authors:  P A Reece; J F Bishop; I N Olver; I Stafford; B L Hillcoat; G Morstyn
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  The disposition of carboplatin in ovarian cancer patients.

Authors:  R C Gaver; N Colombo; M D Green; A M George; G Deeb; A D Morris; R M Canetta; J L Speyer; R H Farmen; F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.

Authors:  S J Harland; D R Newell; Z H Siddik; R Chadwick; A H Calvert; K R Harrap
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

7.  Liquid chromatographic procedure for the quantitative analysis of carboplatin in beagle dog plasma ultrafiltrate.

Authors:  G F Duncan; H C Faulkner; R H Farmen; K A Pittman
Journal:  J Pharm Sci       Date:  1988-03       Impact factor: 3.534

8.  The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.

Authors:  Z H Siddik; D R Newell; F E Boxall; K R Harrap
Journal:  Biochem Pharmacol       Date:  1987-06-15       Impact factor: 5.858

9.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

Authors:  A H Calvert; D R Newell; L A Gumbrell; S O'Reilly; M Burnell; F E Boxall; Z H Siddik; I R Judson; M E Gore; E Wiltshaw
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

10.  Phase I studies with carboplatin at the Royal Marsden Hospital.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; K R Harrap
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

View more
  6 in total

Review 1.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics and dose optimisation of carboplatin.

Authors:  S B Duffull; B A Robinson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

3.  The use of the Calvert formula to determine the optimal carboplatin dosage.

Authors:  L J van Warmerdam; S Rodenhuis; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 4.  Chemotherapy individualization.

Authors:  Gareth J Veal; Sally A Coulthard; Alan V Boddy
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

5.  Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.

Authors:  L J van Warmerdam; S Rodenhuis; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

6.  Comparative Pharmacokinetics and Allometric Scaling of Carboplatin in Different Avian Species.

Authors:  Gunther Antonissen; Mathias Devreese; Siegrid De Baere; Tom Hellebuyck; Isabel Van de Maele; Lieze Rouffaer; Hendrickus J J Stemkens; Patrick De Backer; An Martel; Siska Croubels
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.